Skip to main content
PMC home page
Sexually Transmitted Infections logoLink to Sexually Transmitted Infections
. 2001 Aug;77(4):283–286. doi: 10.1136/sti.77.4.283

Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype

M Shahmanesh 1, H Jaleel 1, Y DeSilva 1, J Ross 1, M Caslake 1, R Cramb 1
PMCID: PMC1744346  PMID: 11463929

Abstract

Objective: To determine the prevalence of type III hyperlipoproteinaemia in a cohort of HIV infected patients taking protease inhibitors and its correlation with the apolipoprotein-E2 isoform.

Design: Cross sectional study of 57 consecutive HIV infected subjects taking protease inhibitor therapy for a median of 12.5 (1–29) months, seen in an outpatient HIV clinic. Controls were 17 patients on non-nucleoside reverse transcriptor inhibitor therapy (NNRTI) for 9 (1–19) months and 50 antiviral naive patients.

Methods: Fasting cholesterol, triglyceride, HDL cholesterol, lipoprotein (a), and glucose were measured. Lipoprotein electrophoresis was performed on patients with a cholesterol >6.5 mmol/l and a triglyceride concentration of >4.5 mmol/l. Apolipoprotein-E phenotype was determined in serum.

Results: Dyslipidaemia was found in 43 (75%) PI treated patients—37 with triglyceride >2.3 mmol/l, 30 with cholesterol >6.5 mmol/l, and nine with HDL cholesterol <0.9 mmol/l. 38% had a lipoprotein (a) >300 mg/l. 11 patients (19.3%) had a type III hyperlipoproteinaemia pattern. Only one was homozygous for the E2 phenotype and none had clinical diabetes. An additional patient had a serum lipid profile compatible with type III hyperlipoproteinaemia and an E3/E2 phenotype in whom electrophoresis was not carried out before treatment. Six (35%) of the NNRTI and 16 (32%) of the antiviral naive patients had dyslipidaemia. 18 (31.6%) of the PI and none of the control patients had a cholesterol and/or triglyceride >8 mmol/l.

Conclusion: Type III hyperlipoproteinaemia is common in this group of patients and need not be associated with the apolipoprotein-E2/E2 isoform. HIV protease inhibitors may interfere with lipoprotein receptor related protein.

Key Words: HIV; protease inhibitors; hyperlipidaemia; apolipoprotein-E

Full Text

The Full Text of this article is available as a PDF (96.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barreiro P., Soriano V., Blanco F., Casimiro C., de la Cruz J. J., González-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 2000 May 5;14(7):807–812. doi: 10.1097/00002030-200005050-00006. [DOI] [PubMed] [Google Scholar]
  2. Behrens G., Dejam A., Schmidt H., Balks H. J., Brabant G., Körner T., Stoll M., Schmidt R. E. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999 Jul 9;13(10):F63–F70. doi: 10.1097/00002030-199907090-00001. [DOI] [PubMed] [Google Scholar]
  3. Bonnet E., Ruidavets J. B., Tuech J., Ferrières J., Collet X., Fauvel J., Massip P., Perret B. Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab. 2001 Jan;86(1):296–302. doi: 10.1210/jcem.86.1.7164. [DOI] [PubMed] [Google Scholar]
  4. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D. J., Cooper D. A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998 May 7;12(7):F51–F58. doi: 10.1097/00002030-199807000-00003. [DOI] [PubMed] [Google Scholar]
  5. Carr A., Samaras K., Chisholm D. J., Cooper D. A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998 Jun 20;351(9119):1881–1883. doi: 10.1016/S0140-6736(98)03391-1. [DOI] [PubMed] [Google Scholar]
  6. Carr A., Samaras K., Thorisdottir A., Kaufmann G. R., Chisholm D. J., Cooper D. A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999 Jun 19;353(9170):2093–2099. doi: 10.1016/S0140-6736(98)08468-2. [DOI] [PubMed] [Google Scholar]
  7. Christeff N., Melchior J. C., de Truchis P., Perronne C., Nunez E. A., Gougeon M. L. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS. 1999 Nov 12;13(16):2251–2260. doi: 10.1097/00002030-199911120-00007. [DOI] [PubMed] [Google Scholar]
  8. Fredrickson D. S., Morganroth J., Levy R. I. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med. 1975 Feb;82(2):150–157. doi: 10.7326/0003-4819-82-2-150. [DOI] [PubMed] [Google Scholar]
  9. Grunfeld C., Kotler D. P., Hamadeh R., Tierney A., Wang J., Pierson R. N. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989 Jan;86(1):27–31. doi: 10.1016/0002-9343(89)90225-8. [DOI] [PubMed] [Google Scholar]
  10. Havekes L. M., de Knijff P., Beisiegel U., Havinga J., Smit M., Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987 Apr;28(4):455–463. [PubMed] [Google Scholar]
  11. Hellerstein M. K., Grunfeld C., Wu K., Christiansen M., Kaempfer S., Kletke C., Shackleton C. H. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab. 1993 Mar;76(3):559–565. doi: 10.1210/jcem.76.3.8445011. [DOI] [PubMed] [Google Scholar]
  12. Hokanson J. E., Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213–219. [PubMed] [Google Scholar]
  13. Kostner G. M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qunici G. B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981 Jan-Feb;38(1-2):51–61. doi: 10.1016/0021-9150(81)90103-9. [DOI] [PubMed] [Google Scholar]
  14. Lister R. K., Youle M., Nair D. R., Winder A. F., Rustin M. H. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet. 1999 May 15;353(9165):1678–1678. doi: 10.1016/s0140-6736(99)01449-x. [DOI] [PubMed] [Google Scholar]
  15. Mauss S., Wolf E., Jaeger H. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors. Ann Intern Med. 1999 Jan 19;130(2):162–163. doi: 10.7326/0003-4819-130-2-199901190-00019. [DOI] [PubMed] [Google Scholar]
  16. Miller K. D., Jones E., Yanovski J. A., Shankar R., Feuerstein I., Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998 Mar 21;351(9106):871–875. doi: 10.1016/S0140-6736(97)11518-5. [DOI] [PubMed] [Google Scholar]
  17. Penzak S. R., Chuck S. K. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000;32(2):111–123. doi: 10.1080/003655400750045196. [DOI] [PubMed] [Google Scholar]
  18. Purnell J. Q., Zambon A., Knopp R. H., Pizzuti D. J., Achari R., Leonard J. M., Locke C., Brunzell J. D. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000 Jan 7;14(1):51–57. doi: 10.1097/00002030-200001070-00006. [DOI] [PubMed] [Google Scholar]
  19. Périard D., Telenti A., Sudre P., Cheseaux J. J., Halfon P., Reymond M. J., Marcovina S. M., Glauser M. P., Nicod P., Darioli R. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999 Aug 17;100(7):700–705. doi: 10.1161/01.cir.100.7.700. [DOI] [PubMed] [Google Scholar]
  20. Thomas J. C., Lopes-Virella M. F., Del Bene V. E., Cerveny J. D., Taylor K. B., McWhorter L. S., Bultemeier N. C. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000 Jun;20(6):727–734. doi: 10.1592/phco.20.7.727.35179. [DOI] [PubMed] [Google Scholar]
  21. Walli R., Herfort O., Michl G. M., Demant T., Jäger H., Dieterle C., Bogner J. R., Landgraf R., Goebel F. D. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998 Oct 22;12(15):F167–F173. doi: 10.1097/00002030-199815000-00001. [DOI] [PubMed] [Google Scholar]
  22. White A. J. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001 Jun;77(3):158–173. doi: 10.1136/sti.77.3.158. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Sexually Transmitted Infections are provided here courtesy of BMJ Publishing Group

RESOURCES